LYON, France, Sep 11, 2008 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today its schedule to participate in national and local patient outreach efforts during prostate cancer awareness month. The Company hopes to increase its visibility among the prostate cancer patient and physician community as the leader in non-invasive therapeutic ultrasound. EDAP's presence is also aimed at accelerating recruitment efforts for patient enrollment in the U.S. ENLIGHT trial.

 Event: Prostate Cancer Research Institute Conference
 Date: Saturday, September 6 - Sunday, September 7, 2008
 Location: Los Angeles, California

 Event: Greater Chicago Prostate Cancer Run, Walk 'n Roll
 Date: Sunday, September 14, 2008
 Location: Chicago, Illinois

 Event: Dash for Dad
 Date: September 28, 2008
 Location: Washington, D.C.

Marc Oczachowski, EDAP's Chief Executive Officer stated, "National Prostate Cancer Awareness Month is an excellent opportunity to underscore EDAP's commitment to the effective prevention and treatment of localized prostate cancer. Our presence at these events is reflective of our efforts to increase patient awareness of Ablatherm HIFU's non-invasive and safe ultrasound therapy through local media outreach and our recently implemented grass roots programs targeting patient, advocacy and senior groups in cites where our clinical sites are located. With this momentum driving the ENLIGHT trial, we have seen an increase in the pace of enrollment, which we believe is a reflection of the unmet need for a minimally invasive treatment approach to prostate cancer. We are pleased that Ablatherm-HIFU is building momentum in the United States, based on our unique expertise in HIFU as we anticipate continued treatment ramp up for our U.S. clinical study which will be submitted to the FDA in application for approval."

EDAP sponsored the attendance of the Los Angeles-based ENLIGHT investigator and his study coordinator at The Prostate Cancer Research Institute Conference, which was attended by prostate cancer survivors, family members, patient advocates, physicians, and researchers. In addition to support group meetings to increase awareness for the ENLIGHT clinical trial, PAACT (Patient Advocates for Advanced Cancer Treatments, Inc.) devoted part of its booth space to distribute information on ENLIGHT.

At the Greater Chicago Prostate Cancer Run, Walk 'n Roll, EDAP is sponsoring a booth, where information on ENLIGHT will be distributed and discussed. In addition, the ENLIGHT study will appear on event tee shirts and web site, and study materials will be distributed in attendee packets.

At the end of September, EDAP is considering sponsorship at Dash for Dad. The event will take place in Washington, D.C., which has the highest rate of prostate cancer death in the United States.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and http://www.pcaresearch.com or http://www.urotoday.com/HIFU.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: EDAP TMS S.A.

EDAP TMS SA
          Investor Relations / Legal Affairs
          Blandine Confort
          +33 4 72 15 31 72
          bconfort@edap-tms.com  

          The Ruth Group
          Investors:
          R.J. Pellegrino
          646-536-7009
          rpellegrino@theruthgroup.com

(C) Copyright 2008 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX